Title
Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
Date Issued
01 March 2021
Access level
open access
Resource Type
journal article
Author(s)
Columbia University Irving Medical Center
Publisher(s)
Adis
Start page
129
End page
131
Volume
5
Issue
1
Language
English
OCDE Knowledge area
Sistema respiratorio
Virología
Scopus EID
2-s2.0-85097557523
Source
PharmacoEconomics - Open
ISSN of the container
25094262
Sponsor(s)
This study was supported in part by the National Institutes of Health (Grant numbers UL1 TR001873 to MRB and K23 HL 150280 to MRA) and the Parker B Francis Foundation. None of the listed funding sources were involved in the design or conduct of this study; the collection, management, analysis or interpretation of data; the preparation, review, or approval of this manuscript; or the decision to submit this manuscript for publication.
Dr. Anderson has no conflicts of interest that are directly relevant to the content of this article. Dr. Baldwin served as site co-investigator for Gilead Sciences Remdesivir trials GS-US-540-5774 and GS-US-540-5773 and received no funding. Dr. Bach has received personal fees and non-financial support from the American Society for Health-System Pharmacists, United Rheumatology, Oppenheimer & Co, Kaiser Permanente Institute for Health Policy, the Congressional Budget Office, America’s Health Insurance Plans, and Geisinger; personal fees from WebMD, Defined Health, JMP Securities, Mercer, Foundation Medicine, Grail, Morgan Stanley, NYS Rheumatology Society, Cello Health, Anthem, Magellan Health, EQRx, Meyer Cancer Center of Weill Cornell Medicine, and the National Pharmaceutical Council; personal fees, non-financial support, and other support from Oncology Analytics; and grants from Kaiser Permanente and Arnold Ventures. All listed support was outside the submitted work.
Sources of information:
Directorio de Producción Científica
Scopus